ROME, Italy – Gain Therapeutics, Inc. recently held a Special Call on July 1, 2024, to provide updates on its corporate and business activities. The call featured Company Participants like Apaar Jammu, Manager of Investor Relations, and Gene Mack, the Chief Financial Officer & Interim Chief Executive Officer.

During the call, Apaar Jammu emphasized the importance of legal disclosures on forward-looking statements. Gain Therapeutics, a clinical-stage biotechnology company, highlighted the development of their lead molecule, GT-02287, currently in Phase 1 clinical trials for Parkinson’s disease treatment. The company also shared plans to advance their portfolio of molecules into clinical development.

Gene Mack, who took on the role of CEO on an interim basis following the departure of Former CEO Matthias Alder, discussed recent management changes. Dr. Khalid Islam was appointed as Executive Chairman to support the management team in clinical planning and operations, as well as regulatory planning and strategy.

The company successfully completed an $11 million public offering to support the continued development of GT-02287 for neurodegenerative diseases. This funding allows Gain Therapeutics to initiate a Phase 1b proof of concept study in patients with Parkinson’s disease.

The Phase 1 trial of GT-02287 demonstrated promising safety and tolerability profiles, paving the way for further investigation in patients. The company aims to present full results at an upcoming conference in September, showcasing the potential of GT-02287 to slow disease progression in Parkinson’s patients.

At the 2024 Annual Federation of European Neurosciences Forum, Gain Therapeutics presented data supporting the cognitive improvement observed with GT-02287 administration in a mouse model of GBA1 Parkinson’s disease. This data, along with preclinical studies, indicates the potential of GT-02287 in addressing the underlying mechanisms of Parkinson’s disease progression.

Moving forward, Gain Therapeutics remains focused on advancing GT-02287 through clinical development and engaging with regulatory agencies like the FDA. The company’s commitment to addressing the unmet medical needs of Parkinson’s disease patients drives their efforts in developing innovative treatment options.

As Gain Therapeutics continues to make strides in therapeutic development, stakeholders look forward to future updates and advancements in the field of neurodegenerative disease treatment.